Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves new kind of treatment for hairy cell leukemia


SILVER SPRING, Md., Sept. 13, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Lumoxiti fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "This therapy is the result of important research conducted by the National Cancer Institute that led to the development and clinical trials of this new type of treatment for patients with this rare blood cancer."

HCL is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look "hairy" when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.

The efficacy of Lumoxiti was studied in a single-arm, open-label clinical trial of 80 patients who had received prior treatment for HCL with at least two systemic therapies, including a purine nucleoside analog. The trial measured durable complete response (CR), defined as maintenance of hematologic remission for more than 180 days after achievement of CR. Thirty percent of patients in the trial achieved durable CR, and the overall response rate (number of patients with partial or complete response to therapy) was 75 percent.

Common side effects of Lumoxiti include infusion-related reactions, swelling caused by excess fluid in body tissue (edema), nausea, fatigue, headache, fever (pyrexia), constipation, anemia and diarrhea.

The prescribing information for Lumoxiti includes a Boxed Warning to advise health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels into surrounding tissues. Symptoms of capillary leak syndrome include difficulty breathing, weight gain, hypotension, or swelling of arms, legs and/or face. The Boxed Warning also notes the risk of  hemolytic uremic syndrome, a condition caused by the abnormal destruction of red blood cells. Patients should be made aware of the importance of maintaining adequate fluid intake, and blood chemistry values should be monitored frequently. Other serious warnings include: decreased renal function, infusion-related reactions and electrolyte abnormalities. Women who are breastfeeding should not be given Lumoxiti.

The FDA granted this application Fast Track and Priority Review designations. Lumoxiti also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The FDA granted the approval of Lumoxiti to AstraZeneca Pharmaceuticals.

For more information:

NIH: Hairy Cell Leukemia
FDA: Office of Hematology and Oncology Products 
FDA: Approved Drugs: Questions and Answers
FDA: Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669, [email protected]
Consumer Inquiries: 888-INFO-FDA

 

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 21:51
On March 19, DMEGC Solar received the Acknowledgement of Manufacturer's Laboratory Competence issued by TÜV Rheinland, a global certification agency, proving its excellence in PV module R&D and quality control. The acknowledgement is TÜV Rheinland's...

at 21:45
Shop TJC Ltd. (TJC) is thrilled to announce the successful completion of its third collaboration with the iconic BBC...

at 21:32
Arctech has recently signed a contract for the 500MW Manah I power plant project in Oman, following its successful bid for the 588MW Manah II PV project in Oman earlier in 2023. This consecutive project win showcases Arctech's customized solutions...

at 21:15
Techtouch, Inc. (Headquarter: Tokyo, Japan, President/CEO: Naka Imuta) announced today that it ranked 8th in the 21st Technology Fast 50 Japan, with three-year revenue growth of 468.6%. Technology Fast 50 Japan, held annually by Deloitte Tohmatsu...

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...

at 21:00
The "Strategic Storytelling for Internal Communications: Using the Power of Storytelling to Engage Employees, Manage Organizational Change, and Shape Workplace Cultures" conference has been added to  ResearchAndMarkets.com's offering. The Best...



News published on and distributed by: